{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-233693","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.716182+00:00","generated_at":"2026-06-10T19:08:06.330657+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CFO August Moretti retires; Uneek Mehra appointed as CFO effective Sept 11, 2023","bullets":["August J. Moretti retired as CFO effective Sept 11, 2023; will serve as Senior Business Advisor through 2023 then consultant through Dec 2024 at $18k/month.","Uneek Mehra appointed CFO, Principal Financial and Accounting Officer; base salary $510k, target bonus 45%, option grant of 229,634 shares.","Mehra previously served as CFO at Myovant Sciences (Sept 2021-July 2023) and PACT Pharma.","Sign-on bonus of $200k in two installments; severance includes 9 months base salary and COBRA reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-233693","json":"https://secwatch.observer/filing/0001193125-23-233693.json","markdown":"https://secwatch.observer/filing/0001193125-23-233693.md","text":"https://secwatch.observer/filing/0001193125-23-233693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/0001193125-23-233693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/d387807d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:08:06.330657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1df1fc0685","claim":"Uneek Mehra was appointed as Chief Financial and Business Officer at 4D Molecular Therapeutics, Inc..","evidence_excerpt":"announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/0001193125-23-233693-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"joined"},{"label":"Role","value":"Chief Financial and Business Officer"}],"fact_type":"executive_change"},{"claim_id":"6c1c83bad7","claim":"August J. Moretti departed as Chief Financial Officer at 4D Molecular Therapeutics, Inc..","evidence_excerpt":"announced that August J. Moretti will retire as Chief Financial Officer and Assistant Secretary of the Company, effective September 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/0001193125-23-233693-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}